Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-JH040182
- Development stage
- Phase 1
- Lead developer
- The First Hospital of Fujian Medical University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
177Lu-JH040182 is a novel radiopharmaceutical consisting of the beta-emitting radioisotope Lutetium-177 conjugated to a ligand targeting Fibroblast Activation Protein (FAP). FAP is a cell-surface glycoprotein that is highly expressed in the tumor stroma of various epithelial cancers, particularly on cancer-associated fibroblasts (CAFs), while showing minimal expression in normal adult tissues. This differential expression makes FAP an attractive target for theranostic applications. Developed by the First Affiliated Hospital of Fujian Medical University, 177Lu-JH040182 is designed to deliver targeted cytotoxic radiation directly to the tumor microenvironment. It is currently being evaluated in first-in-human Phase 1 clinical trials to assess its safety, biodistribution, and internal radiation dosimetry in patients with advanced metastatic FAP-positive malignancies.
- Other names
- 177Lu-FAPILutetium-177 JH040182Lutetium177 JH040182Lutetium 177 JH040182
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 177Lu-JH040182.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-JH040182.